Login Register Cart 0
Generic placeholder image

Recent Patents on Nanotechnology

Editor-in-Chief

ISSN (Print): 1872-2105
ISSN (Online): 2212-4020

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Opinion Article

Polymeric Nanoparticles for the Treatment of Prostate Cancer- Technological Prospecting and Critical Analysis

Author(s): Clauberto Rodrigues de Oliveira, Daniela Droppa-Almeida*, Francine Ferreira Padilha, Roberto Rodrigues de Souza and Ricardo Luiz Cavalcanti de Albuquerque-Júnior

Volume 17, Issue 1, 2023

Published on: 10 March, 2022

Page: [8 - 14] Pages: 7

DOI: 10.2174/1872210516666220131092642

Price: $65

Abstract

Background: Polymeric nanoparticles have a wide diversity, and due to their toxicity and biodegradability, they have been widely used in the health area. Its use allows stability of some compounds, targeted delivery, and increased half-life, in this context, making some treatment proposals more effective. Prostate cancer, in turn, is among the types of cancer with the highest mortality, and the lack of effective treatment causes several strategies to meet this need.

Objective: The objective of this work was to verify patents that use polymeric nanoparticles for the treatment of prostate cancer.

Methods: For that, specific keywords to direct the search were applied in Patent Scope. After obtaining the patents, one was selected for the development of critical analysis in relation to its chemistry and biology.

Results: A total of five patents were found and, of these, an invention that used PCL-PLGA-PEGCOOH polymeric nanoparticles with two natural compounds, resveratrol and celastrol, providing an alternative method to traditional monotherapies.

Conclusion: The prospective analysis serves to direct us in relation to the technologies currently used in certain fields. Based on several cases of cancer and specifically the countless cases of prostate cancer, five recent patents were found using polymeric nanoparticles. However, only one brought a different aspect of all the treatments used lately. It brought an invention containing two natural compounds being carried with polymeric nanoparticles with promising results.

Keywords: Bioactive compounds, nanosystems, chemoprevention, chemotherapy, prostate cancer, nanoparticles.

« Previous Next »
Graphical Abstract

[1]
Duncan R, Gaspar R. Nanomedicine (s) under the microscope. Mol Pharm 2011; 8(6): 2101-41.
[http://dx.doi.org/10.1021/mp200394t]
[2]
Rao DA, Forrest ML, Alani AWG, Kwon GS, Robinson JR. Biodegradable PLGA based nanoparticles for sustained regional lymphatic drug delivery. J Pharm Sci 2010; 99(4): 2018-31.
[http://dx.doi.org/10.1002/jps.21970] [PMID: 19902520]
[3]
Khare V, Kour S, Alam N, et al. Synthesis, characterization and mechanistic-insight into the anti-proliferative potential of PLGA-gemcitabine conjugate. Int J Pharm 2014; 470(1-2): 51-62.
[http://dx.doi.org/10.1016/j.ijpharm.2014.05.005] [PMID: 24810239]
[4]
Sah H, Thoma LA, Desu HR, Sah E, Wood GC. Concepts and practices used to develop functional PLGA-based nanoparticulate systems. Int J Nanomedicine 2013; 8: 747-65.
[http://dx.doi.org/10.2147/IJN.S40579]
[5]
Pamujula S, Hazari S, Bolden G, et al. Cellular delivery of PEGylated PLGA nanoparticles. J Pharm Pharmacol 2012; 64(1): 61-7.
[http://dx.doi.org/10.1111/j.2042-7158.2011.01376.x] [PMID: 22150673]
[6]
Messina C, Cattrini C, Soldato D, et al. BRCA mutations in prostate cancer: Prognostic and predictive implications. J Oncol 2020; 2020: 4986365.
[http://dx.doi.org/10.1155/2020/4986365] [PMID: 32963528]
[7]
Saoud R, Heidar NA, Cimadamore A, Paner GP. Incorporating prognostic biomarkers into risk assessment models and TNM staging for prostate cancer. Cells 2020; 9(9): 2116.
[http://dx.doi.org/10.3390/cells9092116] [PMID: 32957584]
[8]
Jasiński M, Jasińska L, Ogrodowczyk M. Resveratrol in prostate diseases - A short review. Cent European J Urol 2013; 66(2): 144-9.
[http://dx.doi.org/10.5173/ceju.2013.02.art8]
[9]
Hawks C, Moe A, McCombie S, Hamid A, Brown M, Hayne D. One stop prostate clinic: Prospective analysis of 1000 men attending a public same-day prostate cancer assessment and/or diagnostic clinic. ANZ J Surg 2020; 91(4): 558-64.
[http://dx.doi.org/10.1111/ans.16329]
[10]
Sanna V, Chamcheu JC, Pala N, Mukhtar H, Sechi M, Siddiqui IA. Nanoencapsulation of natural triterpenoid celastrol for prostate cancer treatment. Int J Nanomedicine 2015; 10: 6835-46.
[http://dx.doi.org/10.2147/IJN.S93752] [PMID: 26586945]
[11]
Kim YA, Rhee SH, Park KY, Choi YH. Antiproliferative effect of resveratrol in human prostate carcinoma cells. J Med Food 2003; 6(4): 273-80.
[http://dx.doi.org/10.1089/109662003772519813] [PMID: 14977434]
[12]
Guo J, Huang X, Wang H, Yang H. Celastrol induces autophagy by targeting AR/miR-101 in prostate cancer cells. PLoS One 2015; 10(10): e0140745.
[http://dx.doi.org/10.1371/journal.pone.0140745] [PMID: 26473737]
[13]
Saranyutanon S, Deshmukh SK, Dasgupta S, Pai S, Singh S, Singh AP. Cellular and molecular progression of prostate cancer: Models for basic and preclinical research. Cancers 2020; 12(9): 1-26.
[http://dx.doi.org/10.3390/cancers12092651]
[14]
Selvaraj S, Sun Y, Sukumaran P, Singh BB. Resveratrol activates autophagic cell death in prostate cancer cells via downregulation of STIM1 and the mTOR pathway. Mol Carcinog 2016; 55(5): 818-31.
[http://dx.doi.org/10.1002/mc.22324] [PMID: 25917875]
[15]
Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Préat V. PLGA-based nanoparticles: An overview of biomedical applications. J Control Release 2012; 161(2): 505-22.
[http://dx.doi.org/10.1016/j.jconrel.2012.01.043] [PMID: 22353619]
[16]
Mukherjee S, Ghosh RN, Maxfield FR. Endocytosis. Physiol Rev 1997; 77(3): 759-803.
[http://dx.doi.org/10.1152/physrev.1997.77.3.759]
[17]
Panyam J, Zhou WZ, Prabha S, Sahoo SK, Labhasetwar V. Rapid endo-lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: Implications for drug and gene delivery. FASEB J 2002; 16(10): 1217-26.
[http://dx.doi.org/10.1096/fj.02-0088com] [PMID: 12153989]
[18]
Owens DE, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm 2006; 307(1): 93-102.
[http://dx.doi.org/10.1016/j.ijpharm.2005.10.010]
[19]
Nagarwal RC, Kant S, Singh PN, Maiti P, Pandit JK. Polymeric nanoparticulate system: A potential approach for ocular drug delivery. J Control Release 2009; 136(1): 2-13.
[http://dx.doi.org/10.1016/j.jconrel.2008.12.018]
[20]
Sanna V, Siddiqui IA, Sechi M, Mukhtar H. Resveratrol-loaded nanoparticles based on poly(epsilon-caprolactone) and poly(D,L-lactic-co-glycolic acid)-poly(ethylene glycol) blend for prostate cancer treatment. Mol Pharm 2013; 10(10): 3871-81.
[http://dx.doi.org/10.1021/mp400342f] [PMID: 23968375]
[21]
Ahmadi R, Ebrahimzadeh MA. Resveratrol – A comprehensive review of recent advances in anticancer drug design and development. Eur J Med Chem 2020; 200: 112356.
[http://dx.doi.org/10.1016/j.ejmech.2020.112356]
[22]
Hou W, Liu B, Xu H. Celastrol: Progresses in structure-modifications, structure-activity relationships, pharmacology and toxicology. Eur J Med Chem 2020; 189: 112081.
[http://dx.doi.org/10.1016/j.ejmech.2020.112081]
[23]
Sah H. Microencapsulation techniques using ethyl acetate as a dispersed solvent: Effects of its extraction rate on the characteristics of PLGA microspheres. J Control Release 1997; 47(3): 233-45.
[http://dx.doi.org/10.1016/S0168-3659(97)01647-7]
[24]
Gref R, Minamitake Y, Peracchia MT, Trubetskoy V, Torchilin V, Langer R. Biodegradable long-circulating polymeric nanospheres. Science 1994; 263(5153): 1600-3.
[http://dx.doi.org/10.1126/science.8128245] [PMID: 8128245]
[25]
Suh H, Jeong B, Liu F, Kim SW. Cellular uptake study of biodegradable nanoparticles in vascular smooth muscle cells. Pharm Res 1998; 15(9): 1495-8.
[http://dx.doi.org/10.1023/A:1011982428413] [PMID: 9755907]
[26]
Moshawih S, Rabiatul RB, Kalakotla S, Jarrar QB. Potential application of resveratrol in nanocarriers against cancer: Overview and future trends. J Drug Deliv Sci Technol 2019; 53.
[http://dx.doi.org/10.1016/j.jddst.2019.101187]
[27]
Zhang R, Chen Z, Wu SS, Xu J, Kong LC, Wei P. Celastrol enhances the anti-liver cancer activity of sorafenib. Med Sci Monit 2019; 25: 4068-75.
[http://dx.doi.org/10.12659/MSM.914060] [PMID: 31152143]
[28]
Sanna V, Roggio AM, Posadino AM, et al. Novel docetaxel-loaded nanoparticles based on poly(lactide-co-caprolactone) and poly(lactide-co-glycolide-co-caprolactone) for prostate cancer treatment: Formulation, characterization, and cytotoxicity studies. Nanoscale Res Lett 2011; 6(1): 260.
[http://dx.doi.org/10.1186/1556-276X-6-260] [PMID: 21711774]

Rights & Permissions Print Cite
Article Metrics
6
© 2024 Bentham Science Publishers | Privacy Policy